Investing.com··Jessica MitacekHims & Hers Pivots to Brand-Name GLP-1s as Novo Deal Reshapes Growth Strategy
Hims & Hers reports Q1 earnings May 11 after settling patent dispute with Novo Nordisk, gaining rights to sell Wegovy and Ozempic while discontinuing compounded alternatives.
NVOHIMSGLP-1 drugsFDA regulations